PureTech Health Company Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States.

The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies.

It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders.

In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development.

The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

PureTech Health plc

Country	United Kingdom
Founded	2015
Industry	Biotechnology
Sector	Healthcare
Employees	90
CEO	Bharatt Chowrira

Contact Details

Address: 6 Tide Street Boston, 02210 United States
Phone	617 482 2333
Website	puretechhealth.com

Stock Details

Ticker Symbol	PRTC
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
ISIN Number	GB00BY2Z0H74
SIC Code	2836

Key Executives

Name	Position
Dr. Bharatt M. Chowrira J.D., Ph.D.	Chief Executive Officer and Executive Director
Daphne Zohar	Founder, Senior Advisor and Board Observer
Dr. Robert S. Langer Jr., Ph.D., ScD	Co-Founder and Non-Executive Director
Dr. Eric Elenko Ph.D.	Co-Founder and President
Dr. David R. Elmaleh Ph.D.	Co-Founder and Senior Advisor
Lauren A. White M.B.A.	Chief Financial Officer
Eric Green M.B.A.	Chief Operating Officer
Allison Mead Talbot	Head of Communications and Investor Relations
Charles Sherwood III, J.D., Ph.D.	General Counsel and Company Secretary
Spencer Ball	Senior Vice President of Human Resources